About Pharos iBio
The Best Target & The Best Chemical
- Start-up Challenge
- Foundation Builder
- Growth Leap Forward
-
2016.04
Foundation of Pharos I&BT Co., LTD.
-
2016.06
Certification of Venture Business
-
2016.07
Participation of join research (AML) on R&D support project of the New Drug Development Support Cent @ Ministry of Science and ICT → Derivation of newdrug candidate based on cardiac toxicity prediction using the Chemiverse platform
-
2016.08
Certification of R&D center(Bio & A.I.)
-
2016.12
Acute Myeloid Lekemia(AML) therapeutics technology transfer contract(exclusive development) signed
-
2017.07
Attraction of TIPS investment (₩100 million) from Chungbuk Bio Center for Creative Economy and Innovation
-
2017.08
PHI-101 Start of preclinical Tox study
TIPS R&D, Start-up project (Total ₩580 million)
4th Health and Medical Technology Research and Development project (₩1.05 billion)
-
2017.11
Qubest Bio (CharlesRiver Lab) Non-clinical toxicity test agreement
Attration of individual angel investment funds (₩1.5 billion)
-
2018.07
JHU prof. Donald Small in US, Advisory contrat & joint research
-
2018.08
Successful attraction of series A investment(₩7.5billion) -> Korea investment partners, MiraeAsset Venture Investment, IMM investment, DSC investment
-
2018.11
Calvary Mater Hospital, Royal Prince Alfred Hospital in Australia, Consultation of phase I clinical trials
-
2019.02
Signed agreement on business with Korea Chemical Bank in KRICT (Project of building web-base integrated chemical DB for drug materials)
-
2019.03
Granted of PHI-101 AML patent registration in Korea (Patent No.10-1965326)
-
2019.04
PHI-101 received US Orphan Drug Designation for treatment AML
-
2019.08
Certification of INNOBIZ
Establishment of the local subsidiary in Australia
-
2019.12
TGA in Australia has granted PHI-101 Phase 1 clinical trials
-
2020.01
Contract with Korea Investment & Securities for underwriter
-
2020.02
Approval From Korea MFDS on the IND of Phase 1 clinical trial of PHI-101
-
2020.03
Successful attraction of series B investment(₩16 billion) -> Korea investment partners, MiraeAsset Venture Investment, DSC investment, Company K Partners
Join Ph.D Han, senior researcher of Roche, as CDO
-
2020.04
Joint Research and Technology agreement with Yonsei University Health System (Joint Development of New Drugs for Target Anti-cancer Drugs)
Establishment of the local subsidiary in USA (California, Silicon Valley)
-
2020.08
Pharos iBio, changed its name from Pharos I&BT
-
2020.11
Approval From Korea MFDS on the IND of Phase 1 clinical trial of PHI-101-002
-
2020.12
Contract with the designated auditor for listing
Joint Research and Development agreement with Chungnam National Univ. (Development of new drug platform technology for discovering protein kinase inhibitors.)
-
2021.01
Joint Research and Development agreement with NGENbio (Co-Development of Companion Diagnostics of Next Generation FLT3 inhibitor, PHI-101)
Participating in the 39th J.P. Morgan Healthcare Conference.
-
2021.04
Presentation about preclinical study of Ovarian and Breast cancer at the American Association for Cancer Research (AACR) 2021
Excellent award winner of Health and Medical treatment R&D 2020 (Korea MOHW, KHIDI)
-
2021.06
Pharos iBio Co., Ltd. has secured a ₩18 billion Series C round. → UTC investment, Company K Partners, Solidus investment, Intops investment, LSK investment, KDB Capital, Timefolio Asset Management
-
2021.08
Additional establishment of the Seoul R&D Center(A.I. & Bio)
-
2021.11
Building a synthetic laboratory and bio laboratory at the headquarters.
Designated as a Promising Start-up Company(Blue100) in 2021 by Anyan Business Agency
PHI-501 received US Orphan Drug Designation for treatment AML
-
2021.12
Presentation of early clinical results of PHI-101 AML at the annual conference of the American Society of Hematologi, ASH
-
2022.01
Participating in the 40th J.P. Morgan Healthcare Conference.
-
2022.02
Participating in the UNIST Leukemia High-Precision Bio Research Group
-
2022.03
Preclinical results of PHI-501 presented by the American Cancer Society
MOU on the development of innovative new drugs using Geninus and artificial intelligence closing
-
2022.04
Transfer and joint transfer of new KRAS Inhibitor technology with Yuhan Corporation conclusion of development agreement
-
2022.05
Technical evaluation passed (listed on KOSDAQ technical exception)
-
2022.08
Request for listing preliminary examination (listed on KOSDAQ technical exception)
-
2022.11
Joint Research and Development agreement with SHIN POONG PHARM.CO.,LTD.
-
2022.12
Hannam University signed industry-academic cooperation (biomedical field)
Presentation of Phase I clinical trials data of PHI-101 AML at the annual conference of the American Society of Hematologi, ASH
-
2023.01
Participating in the 41th J.P. Morgan Healthcare Conference
-
2023.03
KOSDAQ Listing Preliminary Review Passed
-
2023.04
AACR Announces PHI-501 Intermediary Research Results
-
2023.05
Submitting a securities report (KOSDAQ)
Sydney University, Australia Signs Joint Research MOU on New Drug Development
-
2023.06
BioUSA Announces Company Selection